TrialBlood advances2024

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.

Nicholas J Short et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.